Top Medical News
As recently diagnosed men wait for their prostate cancer surgery, participating in a community-based, preoperative exercise programme may help improve their overall wellbeing and quality of life, a recent study has found.
Stephen Padilla, 3 days ago
Men who regularly consume inflammation-inducing foods, such as red meat, processed food, fried foods, and sugar-sweetened beverages, among others, tend to have an increased risk of testosterone deficiency (TD), suggests a study.
12 Jun 2021
Some cases of prostate cancer appear to respond well with focal laser ablation (FLA), which boosts failure-free survival, a study has found.
Jairia Dela Cruz, 04 Jun 2021
Injecting a hydrogel spacer is useful for putting some distance between the rectum and prostate during radiotherapy for prostate cancer, a study reports. As a result, radiation exposure in the rectum is minimized, and late gastrointestinal and genitourinary toxicities are reduced.
02 Jun 2021
Use of erythropoietin, a promising neurotrophic factor for neurogenic erectile dysfunction based on preclinical and retrospective data, has failed to improve recovery of erectile function in men undergoing radical prostatectomy for prostate cancer compared to placebo, a study has shown.
Stephen Padilla, 31 May 2021
Vitamin D insufficiency is significantly associated with the risk of developing lower urinary tract symptoms (LUTS), but supplementation may potentially improve these symptoms, according to a study.
Jairia Dela Cruz, 28 May 2021
In men with lower urinary tract symptoms (LUTS) due to benign prostatic obstruction, temporary implantation of the second-generation nitinol device (iTIND) produces marked and durable improvements in symptoms and quality of life, as shown in a study.
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.
26 Nov 2019
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
Elaine Soliven, 12 Mar 2021
Adding apalutamide (APA) to abiraterone acetate and prednisone (AAP) significantly extends radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with AAP only, according to the final analysis of the ACIS* trial presented at ASCO GU 2021.
Audrey Abella, 10 Mar 2021
In an updated analysis of the phase III POUT* trial presented at ASCO GU 2021, peri-operative chemotherapy continued to improve disease-free survival (DFS) compared with surveillance in patients with upper tract urothelial cancer (UTUC).
Roshini Claire Anthony, 09 Mar 2021
Enfortumab vedotin improved overall survival (OS) compared with chemotherapy in patients with previously treated, locally advanced or metastatic urothelial carcinoma (UC), according to interim results of the phase III EV-301 study.
Elvira Manzano, 09 Mar 2021
Cabozantinib reduces the risk of disease progression or death by 40 percent compared with the current standard sunitinib in patients with metastatic papillary renal cell carcinoma (mPRCC) – a primary malignant tumour of the renal tubular epithelium – in the phase 2 SWOG 1500 study.
Audrey Abella, 08 Mar 2021
Intravesical administration of the IL-15RαFc* superagonist N-803 with BCG** demonstrated a strong efficacy and an excellent safety and tolerability profile in patients with BCG-unresponsive high-grade NMIBC*** carcinoma in situ, according to an interim analysis presented at ASCO GU 2021.
Pearl Toh, 06 Mar 2021
The combination therapy of lenvatinib plus pembrolizumab significantly improves survival outcomes compared with the standard-of-care treatment of sunitinib in the first-line setting for advanced renal cell carcinoma (RCC), according to the CLEAR* study presented at the 2021 ASCO GU Cancer Symposium.
Pearl Toh, 04 Mar 2021
Treatment with the PD-1 immune checkpoint inhibitor nivolumab after radical surgery significantly extends disease-free survival (DFS) compared with placebo in patients with muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence, regardless of their PD-L1 status, according to the CheckMate 274 study presented at the 2021 ASCO GUCS.